An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Triple-negative breast cancer (TNBC) is treated with neoadjuvant chemotherapy (NAC). The response to NAC, particularly the probability of a complete pathological response (pCR), guides the surgical approach and adjuvant therapy. We developed a prediction model using a nomogram integrating blood test...

Full description

Bibliographic Details
Main Authors: Wai-Shan Chung, Shin-Cheh Chen, Tai-Ming Ko, Yung-Chang Lin, Sheng-Hsuan Lin, Yung-Feng Lo, Shu-Chi Tseng, Chi-Chang Yu
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cancers
Subjects:
triple-negative breast cancer
neoadjuvant chemotherapy
treatment response prediction
Online Access:https://www.mdpi.com/2072-6694/14/17/4170

Similar Items

Similar Items